WAT

Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Waters Corporation (NYSE:WAT) and its peers. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.3% while next quarter’s revenue guidance was 2% above. Luckily, research tools & consumables stocks have performed well with share prices up 22.5% on average since the latest earnings results. Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. Waters Corporation reported revenues of $1.27 billion, up 91.5% year on year. This print exceeded analysts’ expectations by 4.5%. Overall, it was a very strong quarter for the company with an impressive beat of analysts’ organic revenue estimates and revenue guidance for next quarter exceeding analysts’ expectations. "Thanks to the hard work of our teams, we delivered an excellent first quarter as a combined company," said Udit Batra, Ph...

Milford, Massachusetts-based Waters Corporation (WAT) provides analytical workflow solutions. With a market cap of $37 billion, the company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. The global analytical instrumentation leader is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Tuesday, Aug. 4. Ahead of the event, analysts expect WAT to report a profit of $3.01 per share on a diluted basis, up 2% from $2.95 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Dear Google Stock Fans, Mark Your Calendars for July 13 Taiwan Just Waved a Red Flag for Nvidia Stock Taiwan Semi Stock Is Approaching Fair Value Ahead of July 16. How to Play TSM Here. Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect WAT to report EPS of $14.51, up 10.5% from $13.13 in fiscal 2025. Its EPS is expected to rise 14% year over year to $16.54 in fiscal 2027. WAT stock has underperformed the S&P 500 Index’s ($SPX) 20.6% gains over the past 52 weeks, with shares up 6.7% during this period. Similarly, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 18% returns over the same time frame. WAT underperformed on weak China demand, soft biopharma and industrial spending, BD integration concerns, and downbeat guidance that clouded the near-term life sciences recovery. On May 5, WAT shares surged 13.5% after reporting its Q1 results. Its adjusted EPS of $2.70 surpassed Wall Street expectations of $2.31. The company’s revenue was $1.3 billion, beating Wall Street forecasts of $1.2 billion. WAT expects full-year adjusted EPS in the range of $14.40 to $14.60, and revenue ranging from $6.4 billion to $6.5 billion. Analysts’ consensus opinion on WAT stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 23 analysts covering the stock, 13 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and nine give a “Hold.” WAT’s average analyst price targ...

MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 1, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about. Caspar Tudor, Head of Investor [email protected] View original content:https://www.prnewswire.com/news-releases/waters-corporation-schedules-second-quarter-2026-earnings-conference-call-302816469.html

Over the last six months, Waters Corporation’s shares have sunk to $357.08, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 7.8% gain. This may have investors wondering how to approach the situation. Following the pullback, is this a buying opportunity for WAT? Find out in our full research report, it’s free. Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, Waters Corporation’s 8.5% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). Waters Corporation’s five-year average ROIC was 30.5%, placing it among the best healthcare companies. This illustrates its management team’s ability to invest in highly profitable ventures and produce tangible results for shareholders. We can better understand Research Tools & Consumables companies by analyzing their organic revenue. This metric gives visibility into Waters Corporation’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement. Over the last two years, Waters Corporation’s organic revenue averaged 4.9% year-on-year growth. This performance slightly lagged the sector and suggests it may need to improve its products, pricing, or go-to-market strategy, which can add an extra layer of complexity to its operations. Waters Corporation’s merits more than compensate for its flaws. After the recent drawdown, the stock trades at 23.9× forward P/E (or $357.08 per share). Is now a good time to buy? See for yourself in our in-depth research report, it’s free. ONE MORE THING: Top 6 Stocks for This Wee...

A month has gone by since the last earnings report for Waters (WAT). Shares have added about 8.7% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Waters due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Waters delivered first-quarter 2026 adjusted earnings of $2.70 per share, up 20% year over year and beating the Zacks Consensus Estimate by 16.9%. Revenues jumped 91.5% from the year-ago quarter to $1.27 billion and topped the consensus mark of $1.20 billion by 5.2%.The quarter reflected double-digit organic constant currency (cc) revenue growth of 11%, supported by strength across instruments, chemistry, and service, alongside an early contribution from the recently acquired BD Biosciences and Diagnostic Solutions businesses. Organic revenues increased 13% on a reported basis and 11% at cc, with management noting that orders again outpaced sales. The Analytical Sciences Division rose 12% in cc, led by 8% instrument growth, 13% chemistry growth, and 14% service growth.End-market momentum leaned heavily toward pharma, where the company highlighted mid -teens growth supported by instrument replacement activity and idiosyncratic demand drivers such as GLP-1 manufacturing volume and PFAS testing applications. Academic and government demand also improved, aided by a revitalized high-resolution mass spec portfolio. Less than 90 days after closing the Feb. 9 transaction, Waters said newly acquired Biosciences and Diagnostic Solutions generated $520 million of owned-period revenue, exceeding guidance by $40 million. Leadership attributed the upside to a 180-day growth plan emphasizing tighter funnel discipline, higher field activity and faster decision-making.Pricing discipline and contract compliance are also emerging levers. Management noted it is establishing two deal desks, deploying Waters’ pricing expertise and reviewing reagent rental contracts, identifying roughly 700 out of 1,600 U.S. Diagnostic Solutions contracts as out of compliance, representing a double-digit million-dollar annual shortfall opportunity. Analytical Sciences (former Waters division, excluding the Clinical Busin...

The latest earnings report from Waters Corporation (NYSE:WAT ) disappointed investors. Our analysis suggests that while the headline numbers were soft, there are some positive factors which shareholders may have missed. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. As it happens, Waters issued 65% more new shares over the last year. As a result, its net income is now split between a greater number of shares. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. You can see a chart of Waters' EPS by clicking here. Unfortunately, Waters' profit is down 35% per year over three years. And even focusing only on the last twelve months, we see profit is down 32%. Like a sack of potatoes thrown from a delivery truck, EPS fell harder, down 38% in the same period. Therefore, one can observe that the dilution is having a fairly profound effect on shareholder returns. In the long term, if Waters' earnings per share can increase, then the share price should too. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. On top of the dilution, we should also consider the US$168m impact of unusual items in the last year, which had the effect of suppressing profit. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Waters to produce a higher profit next year, all else being equal. Waters suffered from unusual items which depressed its...

Waters Corporation’s first quarter saw a strong market response, as the company delivered results ahead of Wall Street’s revenue and earnings expectations despite headline sales declining year over year. Management pointed to robust organic growth in its legacy divisions and better-than-expected early performance from recently acquired Biosciences and Diagnostic Solutions businesses. CEO Udit Batra credited the swift execution of a 180-day integration plan and operational improvements for driving momentum, highlighting that both instrument replacement activity and new product launches contributed meaningfully to the quarter’s outcome. Is now the time to buy WAT? Find out in our full research report (it’s free). Revenue: $1.27 billion vs analyst estimates of $1.21 billion (91.5% year-on-year growth, 4.5% beat) Adjusted EPS: $2.70 vs analyst estimates of $2.31 (17% beat) Adjusted EBITDA: $416.3 million vs analyst estimates of $316.9 million (32.9% margin, 31.4% beat) Revenue Guidance for Q2 CY2026 is $1.62 billion at the midpoint, above analyst estimates of $1.57 billion Management slightly raised its full-year Adjusted EPS guidance to $14.50 at the midpoint Operating Margin: -3.7%, down from 22.9% in the same quarter last year Organic Revenue rose 13% year on year (beat) Market Capitalization: $34.17 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Tycho Peterson (Jefferies) asked about the sources and timing of revenue synergies and the impact of pricing actions. CFO Amol Chaubal responded that instrument replacement, service plan attachment, and e-commerce were the main synergy drivers, while additional opportunities from pricing and contract compliance were not yet factored into guidance. Patrick Donnelly (Citi) sought clarity on the durability of instrument demand and the trajectory for biopharma growth. CEO Udit Batra emphasized ongoing replacement cycles, strong biopharma activity in the U.S., Europe, and especially China, and confidence in product positioning for sustained growth. Vijay Kumar (Evercore ISI) questioned the sustainability of growth rates in the acquired business and the prudence of second...

Waters WAT delivered first-quarter 2026 adjusted earnings of $2.70 per share, up 20% year over year and beating the Zacks Consensus Estimate by 16.9%. Revenues jumped 91.5% from the year-ago quarter to $1.27 billion and topped the consensus mark of $1.20 billion by 5.2%. The quarter reflected double-digit organic constant currency (cc) revenue growth of 11%, supported by strength across instruments, chemistry and service, alongside an early contribution from the recently acquired BD Biosciences and Diagnostic Solutions businesses. Organic revenues increased 13% on a reported basis and 11% at cc, with management noting that orders again outpaced sales. The Analytical Sciences Division rose 12% in cc, led by 8% instrument growth, 13% chemistry growth and 14% service growth. End-market momentum leaned heavily toward pharma, where the company highlighted mid -teens growth supported by instrument replacement activity and idiosyncratic demand drivers such as GLP-1 manufacturing volume and PFAS testing applications. Academic and government demand also improved, aided by a revitalized high-resolution mass spec portfolio. Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote Less than 90 days after closing the Feb. 9 transaction, Waters said newly acquired Biosciences and Diagnostic Solutions generated $520 million of owned-period revenue, exceeding guidance by $40 million. Leadership attributed the upside to a 180-day growth plan emphasizing tighter funnel discipline, higher field activity and faster decision-making. Pricing discipline and contract compliance are also emerging levers. Management noted it is establishing two deal desks, deploying Waters’ pricing expertise and reviewing reagent rental contracts, identifying roughly 700 out of 1,600 U.S. Diagnostic Solutions contracts as out of compliance, representing a double-digit million-dollar annual shortfall opportunity. Analytical Sciences (former Waters division, excluding the Clinical Business unit) posted $607 million of revenue compared with $534 million in the year-ago quarter. The Biosciences division (formerly known as BD Biosciences) contributed $232 million during the owned period, with Flow Research and Flow Clinical each growing 7% year over year on an estimated as-reported basis. Reagents grew at a low double-digit rate, while instruments remained pressured by U.S. academi...

Waters Corporation (NYSE:WAT) was one of the stocks on Jim Cramer’s radar as he highlighted AI winners to buy for 2026. Cramer explained why the stock rallied, as he said: Stock market data. Photo by Burak The Weekender on Pexels Waters Corporation (NYSE:WAT) provides systems for liquid chromatography, mass spectrometry, thermal analysis, rheometry, and calorimetry. The company’s technologies are used for research, product development, quality checks, and specialized testing. Cramer discussed the Becton, Dickinson deal during the December 1, 2025, episode, as he stated: While we acknowledge the potential of WAT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.

Achieved double-digit organic growth in legacy businesses, driven by a mid-teens pharma performance and sustained instrument replacement cycles in the U.S. and Europe. Realized immediate outperformance in newly acquired Biosciences and Diagnostic Solutions, exceeding revenue guidance by $40 million due to rapid operational improvements post-February 9 close. Launched a 180-day plan to instill commercial rigor, doubling weekly call rates in some units and establishing deal desks to address historical pricing and contract compliance gaps. Leveraged idiosyncratic growth drivers including GLP-1 testing, PFAS environmental monitoring, and India generics to maintain above-market instrument demand. Successfully navigated China market dynamics, achieving over 50% pharma growth by focusing on biotech CDMOs and emerging innovative domestic pharma companies. Initiated revenue synergy realization ahead of schedule, specifically using the Biosciences channel to drive tandem quadrupole mass spectrometry sales into pharma clinical settings. Raised full-year 2026 organic constant currency revenue guidance to 6.5% to 8%, incorporating $15 million in expected revenue synergies from cross-selling of mass spec. Anticipates a 'Phase II' growth inflection starting in Q3 2026 as the first full tranche of synergies from instrument replacement, service plan attachment, and e-commerce begins contributing. Assumes a prudent 6% organic growth rate for the second half of the year to derisk the outlook against potential macro volatility and fewer working days in Q4. Targets at least 100 basis points of adjusted operating margin expansion annually through 2030, supported by $55 million in cost synergies and organizational optimization. Plans to localize manufacturing of flow instruments in China starting in Q3 to improve market access and mitigate export complexity for high-parameter products. Identified approximately 700 out-of-compliance reagent rental contracts in the U.S. Diagnostic Solutions business, representing a double-digit million annual revenue shortfall opportunity. Noted a $20 million headwind in respiratory testing due to a weak flu season, which impacted pro forma growth rates for the acquired Diagnostic Solutions business. Acknowledged ongoing China-related constraints, including DRG-related headwinds and export restrictions on high-parameter Biosciences products, which a...

Image source: The Motley Fool. Tuesday, May 5, 2026 at 8:30 a.m. ET President & Chief Executive Officer — Dr. Udit Batra Senior Vice President & Chief Financial Officer — Amol Chaubal Vice President, Investor Relations — Caspar Tudor Need a quote from a Motley Fool analyst? Email [email protected] Caspar Tudor: Thank you, Lila, and good morning, everyone. Welcome to Waters Corporation's First Quarter Earnings Call. Joining me today are Dr. Udit Batra, our President and Chief Executive Officer; and Amol Chaubal, our Senior Vice President and Chief Financial Officer. Before we begin, I will cover the cautionary language. In this conference call, we will make various forward-looking statements regarding future events or future financial performance of the company, including the financial and operational impact of Waters combination with the Biosciences and Diagnostic Solutions business of Becton, Dickinson and Company or BD. We will provide guidance regarding possible future results, as well as commentary on potential market and business Waters Corporation over the second quarter of 2026 and full year 2026. These statements are only our present expectations and are subject to risks and uncertainties. Please see the risk factors included within our Form 10-K, our Form 10-Qs, our other SEC filings and the cautionary language included in this morning's earnings release. During today's call, we will refer to certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are attached to our earnings release or in the appendix of the slide presentation accompanying today's call. Unless stated otherwise, all organic revenue growth rates are presented on a constant currency basis and are in comparison to the first quarter of 2025. For acquired company revenue, unless stated otherwise, all results cover our period of ownership from the transaction closing date on February 9, 2026, through to the end of the quarter for acquired company revenue growth rates, unless stated otherwise, all growth rates are presented on an estimated as-reported basis, covering the period of ownership in comparison to the prior year equivalent period that predates Water's ownership. Finally, we do not intend to update our guidance, predictions or projections, except as part of a regularly scheduled earnings release. or as otherwise required by law. On today's call...

Waters (WAT) reported fiscal Q1 adjusted earnings Tuesday of $2.70 per diluted share, up from $2.25